ERBB2 and breast carcinoma: The MetaspHer-study (multicenter, open-label, single-arm safety study of subcutaneous trastuzumab in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer) enrolled 113 women with metastasizing breast cancer [24].